Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
Authors:
- Robin L JonesRJRobin L Jones
- Ian E SmithISIan E Smith
- 1 October 2006
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 7 (10) , 869-874
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)Journal of Clinical Oncology, 2005
- Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancerBritish Journal of Cancer, 2004
- Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone ReceptorsClinical Cancer Research, 2004
- Is there still a role for neoadjuvant therapy in breast cancer?Critical Reviews in Oncology/Hematology, 2003
- Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902Journal of Clinical Oncology, 2001
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.Journal of Clinical Oncology, 1998
- Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.Journal of Clinical Oncology, 1998
- Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapyBritish Journal of Cancer, 1997